logo-loader
viewKromek Group PLC

Kromek Group fully focused on commercialisation; on track to achieve revenue growth

Dr Arnab Basu, the chief executive officer of Kromek Group PLC (LON:KMK), spoke to Proactive London following the release of its interm results to October 2018.

Basu says they're on track to achieve revenue growth and in-line underlying earnings (EBITDA) over the full year.

He adds visibility of revenue for the next six to 24 months continues to increase, which includes visibility of around 86% of the forecast revenue for 2018/19.

Quick facts: Kromek Group PLC

Price: 11.875 GBX

AIM:KMK
Market: AIM
Market Cap: £40.93 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kromek Group CEO details DARPA extension and 'groundbreaking' pathogen...

Kromek Group PLC's (LON:KMK) Dr Arnab Basu speaks to Proactive London's Andrew Scott after reporting they've been awarded an extension to its contract with the Defense Advanced Research Projects Agency (DARPA) to detect and identify pathogens in an urban environment. Under the deal it will be...

on 27/5/20

2 min read